AVALO THERAPEUTICS, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
AVALO THERAPEUTICS, INC. (AVTX) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $4.26 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-11
- AVALO THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $4.26M.
- AVALO THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.91M.
- AVALO THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $0.00.
- AVALO THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $0.00.
- AVALO THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $1.91M.
- AVALO THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $0.00.
- AVALO THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $0.00.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $4.26M 10-Q · filed 2018-05-11 | $6.17M derived: sum of 2 quarters · filed 2018-05-11 | $6.17M derived: sum of 3 quarters · filed 2018-05-11 | $6.17M derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-12-31 | $1.91M 10-K · filed 2018-04-02 | $1.91M derived: sum of 2 quarters · filed 2018-04-02 | $1.91M derived: sum of 3 quarters · filed 2018-04-02 | $1.91M 10-K · filed 2018-04-02 |
| 2017-09-30 | $0.00 10-K · filed 2018-04-02 | $0.00 derived: sum of 2 quarters · filed 2018-04-02 | $0.00 derived: sum of 3 quarters · filed 2018-05-11 | |
| 2017-06-30 | $0.00 10-K · filed 2018-04-02 | $0.00 derived: sum of 2 quarters · filed 2018-05-11 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |